Home›Clinical trials›Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer

A study of a GLP-1 and GIP medicine, tirzepatide, in people with endometrial cancer.

Who can join
Adults 18+, women only, have endometrial cancer, BMI 30+.
What you take
Tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts
The full study runs about 3 years.
What you get
Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.
This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.
Check my fit →
Phase Phase 2Sponsor UNC Lineberger Comprehensive Cancer CenterDrug tirzepatideClass GLP-1/GIPSites 1 USEnrollment target 40

What this study is for

Primary condition: Endometrial Cancer. Also studied in: Endometrial Intraepithelial Neoplasia, Grade 1 Endometrial Endometrioid Carcinoma.

Full scientific study title: Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer.

Who can join

Age18 and upSexFemaleBMI30 or higher

Adults 18+, women only, have endometrial cancer, BMI 30+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.
  • The subject is willing and able to comply with study procedures based on the judgement of the investigator.
  • Age \> 18 years at the time of consent.
  • ECOG ≤ 2 or Karnofsky Performance Status of \>50
  • Histological or cytological evidence/confirmation of endometrial intraepithelial neoplasia (EIN) or grade 1 endometrioid histology endometrial cancer (EC) and scheduled to undergo standard of care hysterectomy and staging.

Key exclusion criteria

  • Active infection requires systemic therapy.
  • Subject is pregnant or breast breastfeeding, or planning to become pregnant at any time during the study
  • Taking any prescription medications or other drugs that influence weight change in the past 3 months.
  • Known sensitivities (i.e., urticaria and eczema) to GIP and GLP-1 receptor agonists.
  • Have type 1 diabetes mellitus or latent autoimmune diabetes in adults, or are receiving treatment with insulin.

Where this trial runs

This trial has 1 sites across 1 state. Site contacts are listed for reference. They are not screening through this trial right now.

North Carolina1 site
  • Lineberger Comprehensive Cancer Center
    Chapel Hill, North Carolina

Timeline

Scheduled start: August 2026. Expected completion: March 2029. Last updated on ClinicalTrials.gov: June 4, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.